Literature DB >> 29923888

Human Myocardium Has a Robust α1A-Subtype Adrenergic Receptor Inotropic Response.

Paul M L Janssen1, Benjamin D Canan1, Ahmet Kilic2, Bryan A Whitson2, Anthony J Baker3.   

Abstract

Recent studies report that a single subtype of α1-adrenergic receptor (α1-AR), the α1A-subtype, mediates robust cardioprotective effects in multiple experimental models of heart failure, suggesting that the α1A-subtype is a potential therapeutic target for an agonist to treat heart failure. Moreover, we recently found that the α1A-subtype is present in human heart. The goal of this study was to assess the inotropic response mediated by the α1A-subtype in human myocardium, and to determine whether the response is downregulated in myocardium from failing human heart. We measured in vitro contractile responses of cardiac muscle preparations (trabeculae) isolated from the right ventricle from nonfailing and failing human hearts. Addition of the α1A-subtype agonist A61603 (100 nM) resulted in a large positive inotropic response (force increased ≈ 2-fold). This response represented ≈70% of the response mediated by the β-adrenergic receptor agonist isoproterenol (1 μM). Moreover, in myocardium from failing hearts, α1A-subtype responses remained robust, and only slightly reduced relative to nonfailing hearts. We conclude that α1A-subtype-mediated inotropy could represent a significant source of inotropic support in the human heart. Furthermore, the α1A-subtype remains functional in myocardium from failing human hearts and thus, might be a therapeutic target to support cardioprotective effects in patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29923888      PMCID: PMC6126952          DOI: 10.1097/FJC.0000000000000604

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  32 in total

1.  The alpha(1B)-adrenergic receptor decreases the inotropic response in the mouse Langendorff heart model.

Authors:  Sean A Ross; Boyd R Rorabaugh; Dan Chalothorn; June Yun; Pedro J Gonzalez-Cabrera; Dan F McCune; Michael T Piascik; Dianne M Perez
Journal:  Cardiovasc Res       Date:  2003-12-01       Impact factor: 10.787

2.  Contrasting inotropic responses to alpha1-adrenergic receptor stimulation in left versus right ventricular myocardium.

Authors:  Guan-Ying Wang; Diana T McCloskey; Sally Turcato; Philip M Swigart; Paul C Simpson; Anthony J Baker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-05-26       Impact factor: 4.733

3.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

Authors: 
Journal:  JAMA       Date:  2000-04-19       Impact factor: 56.272

4.  Differential effects of cocaine on the positive inotropic effect of noradrenaline mediated by alpha1- and beta-adrenoceptors in failing human myocardium.

Authors:  T Skomedal; H Aass; O Geiran; J B Osnes
Journal:  Eur J Pharmacol       Date:  2001-05-11       Impact factor: 4.432

5.  Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction.

Authors:  Xiao-Jun Du; Lin Fang; Xiao-Ming Gao; Helen Kiriazis; Xinheng Feng; Elodie Hotchkin; Angela M Finch; Hervé Chaulet; Robert M Graham
Journal:  J Mol Cell Cardiol       Date:  2004-11       Impact factor: 5.000

6.  Myocardial alpha 1-adrenoceptors mediate positive inotropic effect and changes in phosphatidylinositol metabolism. Species differences in receptor distribution and the intracellular coupling process in mammalian ventricular myocardium.

Authors:  M Endoh; T Hiramoto; A Ishihata; M Takanashi; J Inui
Journal:  Circ Res       Date:  1991-05       Impact factor: 17.367

7.  The Frank-Starling mechanism involves deceleration of cross-bridge kinetics and is preserved in failing human right ventricular myocardium.

Authors:  Nima Milani-Nejad; Benjamin D Canan; Mohammad T Elnakish; Jonathan P Davis; Jae-Hoon Chung; Vadim V Fedorov; Philip F Binkley; Robert S D Higgins; Ahmet Kilic; Peter J Mohler; Paul M L Janssen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-09       Impact factor: 4.733

8.  An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity.

Authors:  JuYoun Beak; Wei Huang; Joel S Parker; Sean T Hicks; Cam Patterson; Paul C Simpson; Anqi Ma; Jian Jin; Brian C Jensen
Journal:  JACC Basic Transl Sci       Date:  2017-02

9.  An Alpha-1A Adrenergic Receptor Agonist Prevents Acute Doxorubicin Cardiomyopathy in Male Mice.

Authors:  Megan D Montgomery; Trevor Chan; Philip M Swigart; Bat-Erdene Myagmar; Rajesh Dash; Paul C Simpson
Journal:  PLoS One       Date:  2017-01-12       Impact factor: 3.240

10.  The Alpha-1A Adrenergic Receptor in the Rabbit Heart.

Authors:  R Croft Thomas; Patrick M Cowley; Abhishek Singh; Bat-Erdene Myagmar; Philip M Swigart; Anthony J Baker; Paul C Simpson
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

View more
  13 in total

1.  Reversal of right ventricular failure by chronic α1A-subtype adrenergic agonist therapy.

Authors:  Patrick M Cowley; Guanying Wang; Philip M Swigart; Anaha Raghunathan; Nikitha Reddy; Pranavi Dulam; David H Lovett; Paul C Simpson; Anthony J Baker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-11-09       Impact factor: 4.733

2.  Stretching single titin molecules from failing human hearts reveals titin's role in blunting cardiac kinetic reserve.

Authors:  Mei-Pian Chen; Salome A Kiduko; Nancy S Saad; Benjamin D Canan; Ahmet Kilic; Peter J Mohler; Paul M L Janssen
Journal:  Cardiovasc Res       Date:  2020-01-01       Impact factor: 10.787

Review 3.  Modeling heart failure in animal models for novel drug discovery and development.

Authors:  Paul M L Janssen; Mohammad T Elnakish
Journal:  Expert Opin Drug Discov       Date:  2019-03-12       Impact factor: 6.098

4.  Electroacupuncture Ameliorates Acute Myocardial Ischemic Injury and Long QT Interval in Mice through the α 1A-Adrenergic Receptor: Electrophysiological, Morphological, and Molecular Evidence.

Authors:  Haiyan Zuo; Shuai Cui; Kun Wang; Xin Wu; Jie Zhou; Qiaoyu Qu; Yan Tong; Shengbing Wu; Meiqi Zhou
Journal:  Oxid Med Cell Longev       Date:  2022-06-30       Impact factor: 7.310

5.  Adrenergic Receptor Regulation of Mitochondrial Function in Cardiomyocytes.

Authors:  Peyton B Sandroni; Kelsey H Fisher-Wellman; Brian C Jensen
Journal:  J Cardiovasc Pharmacol       Date:  2022-09-01       Impact factor: 3.271

6.  α1-Adrenergic receptor regulates papillary muscle and aortic segment contractile function via modulation of store-operated Ca2+ entry in long-tailed ground squirrels Urocitellus undulatus.

Authors:  Alexey S Averin; Ludmila A Andreeva; Svetlana S Popova; Leonid S Kosarsky; Andrey I Anufriev; Miroslav N Nenov; Olga V Nakipova
Journal:  J Comp Physiol B       Date:  2021-07-23       Impact factor: 2.200

Review 7.  Cardiac α1A-adrenergic receptors: emerging protective roles in cardiovascular diseases.

Authors:  Jiandong Zhang; Paul C Simpson; Brian C Jensen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-12-04       Impact factor: 4.733

8.  Site-specific phosphorylation of myosin binding protein-C coordinates thin and thick filament activation in cardiac muscle.

Authors:  Saraswathi Ponnam; Ivanka Sevrieva; Yin-Biao Sun; Malcolm Irving; Thomas Kampourakis
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-15       Impact factor: 11.205

Review 9.  Targeting Adrenergic Receptors in Metabolic Therapies for Heart Failure.

Authors:  Dianne M Perez
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes.

Authors:  Najah Abi-Gerges; Tim Indersmitten; Ky Truong; William Nguyen; Phachareeya Ratchada; Nathalie Nguyen; Guy Page; Paul E Miller; Andre Ghetti
Journal:  Sci Rep       Date:  2020-05-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.